Glenmark Celebrates European Ryaltris Approvals

Has Marketing Authorizations In 13 European Countries; Menarini Set To Launch

Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.

Glenmark Website Screen
Glenmark has received 13 European approvals for Ryaltris • Source: Alamy

Glenmark has announced the approval in 13 European countries of its Ryaltris (olopatadine hydrochloride / mometasone furoate) 665mcg/25mcg nasal spray. The Indian company and marketing partner Menarini are set to begin rolling out the treatment for seasonal and perennial allergic rhinitis in adults and children over 12, following earlier launches in certain other international territories.

Earlier this year, Glenmark revealed that it had concluded its decentralized European marketing authorization application procedure, “paving the way for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Value Added Medicines

  • Neuraxpharm Enters Japanese Market 1

     
    • By 

    Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

  • Hyloris Sets Out Plans To Expand Its Pipeline

     
    • By 

    After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

  • Awards Offers Two Weeks Of Online Networking

     
    • By 

    From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

  • Hyloris And Purna Strike Value-Added Development Deal

     
    • By 

    Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.